We are excited to share our Technology and IP Quarterly, where we round up every need-to-know from the technology and IP space for Q3 2026.

This edition covers the developments we’ve been tracking in technology and IP in Norway and the EU over the past quarter, including:

🔸 A busy quarter for intellectual property, including the CJEU’s first Grand Chamber ruling on freedom of expression as “due cause” in trade mark disputes, and a decision from the EPO’s Enlarged Board of Appeal on amending patent descriptions that is likely to become a key reference point for patent prosecution and claim construction before national courts and the UPC.

🔸 A quarter of high enforcement activity in the digital sphere, with the Commission designating ChatGPT, Reddit and Roblox as Very Large Platforms under the DSA, bringing them under additional obligations from January 2027, alongside a substantial fine against AliExpress under the DSA and against Google under the DMA, and a further substantial fine against Google from the Irish Data Protection Commission under the GDPR.

🔸 Key regulatory developments from the Commission, such as the AI Act’s transparency obligations now in force, and the proposed EU KIDS Act on children’s online safety.

Q3 2026 brought a number of important legal and regulatory developments for the life sciences sector. The Q3 2026 edition of BAHR’s Life Sciences Quarterly gathers the key developments we’ve been tracking in Norway and the EU over the past quarter, including:

• Greater transparency in Norwegian market access, as Nye Metoder begins publishing rationales for decisions adopted by the Decision Forum, providing greater insight into the assessments underlying reimbursement and funding decisions.
• Norway’s proposed implementation of the EU’s SoHO Regulation, which would establish a significantly broader regulatory framework for substances of human origin and bring activities such as platelet-rich plasma (PRP), faecal microbiota transplantation (FMT), donor breast milk and certain adipose-derived cell therapies within a harmonised regulatory framework.
• Major EU legislative developments, including the Council of the European Union’s adoption of the EU Pharma Package, marking a significant milestone in the reform of the EU pharmaceutical framework.
• Key EU regulatory and case law developments, including EFPIA’s response to the EU Biotech Act consultation, MedTech Europe’s comments on the classification of high-risk AI systems, and the CJEU’s judgment in C-427/24 Diagramm Halbach, which provides important guidance on the role of promotional claims in the assessment of whether a product qualifies as a medical device under the MDR.

Q2 2026 brought its own set of legal and regulatory developments in life sciences. The Q2 2026 edition of our Life Sciences Quarterly gathers the developments we’ve been tracking in Norway and the EU over the past quarter, including:

🔸 Recent case law from Norway and the EU, including significant CJEU judgments affecting-, distributor obligations under the MDR, online sales of non-prescription medicines, the use of biological products as reference products in generic marketing authorisation applications, and SPC protection for substances classified as excipients.

🔸 Regulatory updates from Norway and the EU, including the provisional agreement on the Critical Medicines Act, EUDAMED becoming mandatory as of 28 May 2026, changes to the framework for blue prescription medicines, and updated eSubmission guidance in connection with NoMA’s new case management platform (DELE).

We have published this year’s edition of our “Data Centres in Scandinavia” publication, written by our cross-discipline and pan-Scandinavian integrated data centre team. The publication provides a regulatory update on the data centre market in Sweden, Denmark and Norway and key insights into the current state of affairs.

This is a special edition that coincides with an exciting milestone: the opening of our offices in Stockholm and Copenhagen. With teams now across Norway, Sweden and Denmark. The articles in this edition reflect that spirit, bringing a comparative Scandinavian perspective to some of the most pressing issues in international arbitration and dispute resolution.

• 𝐓𝐡𝐞 𝐂𝐚𝐬𝐞 𝐟𝐨𝐫 𝐌𝐨𝐝𝐞𝐫𝐧𝐢𝐬𝐢𝐧𝐠 𝐭𝐡𝐞 𝐍𝐨𝐫𝐰𝐞𝐠𝐢𝐚𝐧 𝐀𝐫𝐛𝐢𝐭𝐫𝐚𝐭𝐢𝐨𝐧 𝐀𝐜𝐭: Our Dispute Resolution team makes the case for targeted, incremental reform of Norwegian arbitration legislation, which is now approaching a quarter-century without a major update. From confidentiality protections and emergency arbitration to early dismissal procedures, we examine how Norway can close the gap with leading arbitral centres such as London, Singapore, and Stockholm.
• 𝐓𝐡𝐢𝐫𝐝-𝐏𝐚𝐫𝐭𝐲 𝐋𝐢𝐭𝐢𝐠𝐚𝐭𝐢𝐨𝐧 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐞 𝐍𝐨𝐫𝐝𝐢𝐜𝐬 𝐚𝐧𝐝 𝐁𝐞𝐲𝐨𝐧𝐝: Once a legal curiosity, third-party funding has matured into a multi-billion-dollar industry reshaping how disputes are financed. This article maps the regulatory landscape across Norway and Sweden, unpacks what funders look for, and highlights the key considerations for parties and practitioners navigating this evolving space.
• 𝐋𝐨𝐨𝐤𝐢𝐧𝐠 𝐎𝐮𝐭𝐰𝐚𝐫𝐝 – 𝐇𝐨𝐰 𝐍𝐨𝐫𝐰𝐚𝐲’𝐬 𝐒𝐮𝐩𝐫𝐞𝐦𝐞 𝐂𝐨𝐮𝐫𝐭 𝐢𝐬 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥𝐢𝐬𝐢𝐧𝐠 𝐀𝐫𝐛𝐢𝐭𝐫𝐚𝐭𝐢𝐨𝐧 𝐋𝐚𝐰: Through a deep dive into three landmark Supreme Court decisions, this article traces Norway’s journey from a parochial arbitration culture to one that actively engages with international best practice and a denationalised approach, exploring what this means for Norway’s future as an arbitral seat.

We hope you enjoy this edition and we welcome any thoughts or questions you may have.

We are pleased to announce the launch of our new Life Sciences Quarterly – Q1 2026 edition.

Q1 2026 has already seen several significant legal and regulatory developments in the life sciences sector, and this edition provides a comprehensive overview of the key updates from Norway and the EU during the first quarter of 2026, including:

• Regulatory updates from Norway affecting the pharmaceutical and medical device sectors
• Important EU developments, including new EMA/FDA joint guidance on the use of AI in medicines development
• Recent case law from both Norway and the EU

We hope you find this edition informative and useful. Please do not hesitate to reach out if you have any questions or would like to discuss any of the topics covered.

We are pleased to share the latest edition of our Technology and IP Quarterly for Q1 2026, written by our multi-disciplinary Technology group.

A great deal has already happened across IP, privacy and digital regulation in 2026, and this edition provides a comprehensive overview of the key legal and regulatory developments in technology and intellectual property from Norway and the EU during the first quarter of 2026, including:

• Key intellectual property case law from Norway, the CJEU and the UPC
• Important updates on the regulatory framework and case law in the digital sphere, including areas such as AI, cybersecurity and data protection

We hope you find this edition informative and useful. Please do not hesitate to reach out if you have any questions or would like to discuss any of the topics covered.

BAHRs virksomhetsgruppe for Kapitalforvaltning og Private Equity har en ledende markedsposisjon innenfor juridisk rådgivning til kapitalforvaltningsbransjen. Vi jobber løpende med spennende saker, og er aktive overfor myndighetene når det gjelder bransjens rammevilkår.

I den 6. utgaven av gruppens periodiske oppdatering byr vi på nærmere innblikk i de siste måneders aktiviteter innenfor fundraising og trender i transaksjonsmarkedet, herunder vår nye pan-skandinaviske M&A-plattform og satsningen i Nord-Norge. Vi ser også nærmere på hva som må til for at Norge skal kunne bli et land for kapitalforvaltning, tar for oss regulatoriske spørsmål, og gir en oppdatering på BAHRs Kapitalforvaltning og Private Equity-gruppe og presenterer gruppens 10 nye medarbeidere.

God lesing og god påske!

The oil and gas industry is a core contributor to the Norwegian economy and a core practice area for BAHR.

Our annual publication, “Oil and Gas in Norway – an introduction,” aims to deliver an overview of the latest developments and the regulatory framework governing petroleum activities on the Norwegian continental shelf (NCS). This publication is designed to offer valuable insights to companies actively participating in the sector, as well as to foreign investors and others interested in the dynamics of the Norwegian oil and gas industry.

This year’s publication features:

• An overview of recent key developments in the industry, highlighting significant trends and changes, encompassing activity levels as well as key policy initiatives such as the upcoming white paper on petroleum activities.
• An update on the regulatory landscape governing petroleum activities on the NCS, emphasizing important legal considerations for both experienced industry players and newcomers considering entering the NCS.

We invite you to download the publication below and encourage you to reach out to us should you wish to discuss any aspects further.

Our offshore wind in Scandinavia report is out, providing key insight into the current state of affairs and the regulatory framework for offshore wind developments in Norway, Sweden and Denmark.